Merus Stock Climbs on Positive Trial Results

Dow Jones

May 23, 2025

By Kelly Cloonan

Shares of Merus jumped after the company posted positive interim data from a trial of its treatment for head and neck cancer.

The stock rose 31% to $54.49 on Friday. Shares have climbed 24% over the past 12 months.

The company on Thursday said data from its phase 2 trial of petosemtamab in combination with pembrolizumab showed an overall response rate of 63% and a 79% overall survival rate at 12 months for patients with head and neck squamous cell carcinoma.

The results are significantly better than for pembrolizumab alone, the control of the company's ongoing phase 3 trial, across nearly every metric, Chief Executive Bill Lundberg said.

Merus plans to share top-line interim data from one or both of its phase 3 trials in 2026, he said.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

May 23, 2025 11:25 ET (15:25 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2537117158"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537117158\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2537117158?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-23 23:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537117158","market":"sh","top_or_hot":-1,"title":"Merus Stock Climbs on Positive Trial Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Merus jumped after the company posted positive interim data from a trial of its treatment for head and neck cancer. \n</p>\n<p>\n  The stock rose 31% to $54.49 on Friday. Shares have climbed 24% over the past 12 months. \n</p>\n<p>\n  The company on Thursday said data from its phase 2 trial of petosemtamab in combination with pembrolizumab showed an overall response rate of 63% and a 79% overall survival rate at 12 months for patients with head and neck squamous cell carcinoma. \n</p>\n<p>\n  The results are significantly better than for pembrolizumab alone, the control of the company's ongoing phase 3 trial, across nearly every metric, Chief Executive Bill Lundberg said. \n</p>\n<p>\n  Merus plans to share top-line interim data from one or both of its phase 3 trials in 2026, he said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 23, 2025 11:25 ET (15:25 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merus Stock Climbs on Positive Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerus Stock Climbs on Positive Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-23 23:25</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Merus jumped after the company posted positive interim data from a trial of its treatment for head and neck cancer. \n</p>\n<p>\n  The stock rose 31% to $54.49 on Friday. Shares have climbed 24% over the past 12 months. \n</p>\n<p>\n  The company on Thursday said data from its phase 2 trial of petosemtamab in combination with pembrolizumab showed an overall response rate of 63% and a 79% overall survival rate at 12 months for patients with head and neck squamous cell carcinoma. \n</p>\n<p>\n  The results are significantly better than for pembrolizumab alone, the control of the company's ongoing phase 3 trial, across nearly every metric, Chief Executive Bill Lundberg said. \n</p>\n<p>\n  Merus plans to share top-line interim data from one or both of its phase 3 trials in 2026, he said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 23, 2025 11:25 ET (15:25 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765992.SGD","symbol_name":"FTIF - Franklin Biotechnology Discovery A Acc SGD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2537117158","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537117158","pubTimestamp":1748013900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Merus jumped after the company posted positive interim data from a trial of its treatment for head and neck cancer.The stock rose 31% to $54.49 on Friday. Shares have climbed 24% over the past 12 months.The company on Thursday said data from its phase 2 trial of petosemtamab in combination with pembrolizumab showed an overall response rate of 63% and a 79% overall survival rate at 12 months for patients with head and neck squamous cell carcinoma.The results are significantly better than for pembrolizumab alone, the control of the company's ongoing phase 3 trial, across nearly every metric, Chief Executive Bill Lundberg said.Merus plans to share top-line interim data from one or both of its phase 3 trials in 2026, he said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","MRUS":"Merus B.V.","BK4139":"生物科技","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"Merus股价因积极的试验结果而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRUS":0.9},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Shares of Merus jumped after the company posted positive interim data from a trial of its treatment for head and neck cancer. \n\n\n  The stock rose 31% to $54.49 on Friday. Shares have climbed 24% over the past 12 months. \n\n\n  The company on Thursday said data from its phase 2 trial of petosemtamab in combination with pembrolizumab showed an overall response rate of 63% and a 79% overall survival rate at 12 months for patients with head and neck squamous cell carcinoma. \n\n\n  The results are significantly better than for pembrolizumab alone, the control of the company's ongoing phase 3 trial, across nearly every metric, Chief Executive Bill Lundberg said. \n\n\n  Merus plans to share top-line interim data from one or both of its phase 3 trials in 2026, he said. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 23, 2025 11:25 ET (15:25 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}